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In 1981, the acquired immunodeficiency syndrome (AIDS) appeared insidiously and mystified 
doctors and scientists alike. No one could have predicted then that it would become, arguably, 
the worst plague in human history. Today, 33 million persons are living with infection by the human 
immunodeficiency virus type 1 (HIV-1), the causative agent of AIDS, while another 25 million have 
already died of this disease.Discovery
Early studies suggested that AIDS was 
a disease transmitted through sex or 
blood that led to the loss of CD4+ T lym-
phocytes. Yet any description of a simi-
lar syndrome was nowhere to be found 
in the medical literature. AIDS was obvi-
ously new, and the race was on to find 
the pathogen responsible. Twenty-five 
years ago this month, Barré-Sinoussi 
et al. (1983) reported the detection of 
reverse transcriptase activity in a cul-
ture of lymph node cells taken from a 
patient with pre-AIDS syndrome. This 
finding, and the morphology of viral par-
ticles found in the culture and visualized 
by electron microscopy (Figure 1, inset 
A), suggested that the etiologic agent 
may be a retrovirus. A year later, Pop-
ovic et al. (1984) described the isolation, 
propagation, and characterization of a 
retrovirus from numerous AIDS patients. 
They also developed an immunoassay to 
show that AIDS cases had antibodies to 
this virus whereas healthy persons did 
not. Later studies would prove that the 
retroviruses identified by the two groups 
were one and the same, and that this 
new agent, subsequently named HIV-1, 
was unequivocally the cause of AIDS.
Characterization
HIV-1 has become not only the most 
studied virus in history but also a model 
system in virology as well as an impor-
tant tool for probing the cellular pro-
cesses manipulated by viruses. The 
HIV-1 life cycle is simple in concept but 
enormously complex in detail, in part 
because it is more elaborate than a 
typical retrovirus and possesses several 
auxiliary genes (Muesing et al., 1985). Years of study have only partly unrav-
eled these details, but en route critical 
discoveries have enabled antiviral drug 
development, have illuminated AIDS 
pathogenesis, and have revealed new 
concepts in viral and cellular biology. For 
example, the early realization that HIV-1 
binds to, and selectively infects, cells 
expressing CD4 (Figure 1) provided a 
satisfying explanation for why AIDS was 
characterized by a profound loss of CD4+ 
T cells (Maddon et al., 1986). Moreover, 
the finding that CD4, while necessary, is 
insufficient to render a cell permissive 
for HIV-1 entry led to studies showing 
that the chemokine receptors CXCR4 or 
CCR5 were also required as coreceptors 
for viral entry (Feng et al., 1996).
As the study of HIV-1 has developed, 
it has become increasingly evident that 
the biology of HIV-1 is intimately linked 
with that of its host cell. This theme is 
exemplified by the unique ways in which 
the HIV-1 proteins Tat and Rev modulate 
viral gene expression. Tat recruits the 
major host RNA polymerase II C-termi-
nal domain kinase to the 5′ end of the 
nascent viral RNA (Wei et al., 1998), 
thereby inducing polymerase phospho-
rylation and efficient elongation of the 
viral transcript (Figure 1). Conversely, the 
Rev protein binds to a second cis-acting 
viral RNA sequence and also contains 
the prototype CRM1-binding nuclear 
export signal (Fornerod et al., 1997). 
This links incompletely spliced viral tran-
scripts that serve as mRNAs for several 
HIV-1 proteins to a host nuclear export 
pathway, thus enabling the expression of 
the complete repertoire of viral proteins. 
These mechanisms result in powerful 
regulation of viral gene expression and Cellprovide an elegant solution to the prob-
lem posed by the need to express nine 
proteins from numerous variably spliced 
viral mRNAs. Moreover, the discovery of 
the mechanisms by which Tat and Rev 
work provided major new insights into 
how both viral and cellular transcrip-
tional elongation is regulated and how 
certain viral and cellular proteins and 
RNAs are moved from the nucleus to the 
cytoplasm.
Other instances of molecular parasit-
ism by HIV-1 have been uncovered—a 
particularly striking example occurs 
during the release of virus particles. 
Normally, the host cell ESCRT proteins 
function on the cytoplasmic face of cel-
lular membranes to mediate membrane 
fission during multivesicular body bio-
genesis and cytokinesis. By mimicking 
sequences of the host cell proteins that 
normally recruit the ESCRT complexes, 
HIV-1 diverts this machinery to sites of 
viral particle assembly to enable the 
topologically equivalent fission of cel-
lular and nascent virion membranes 
(Garrus et al., 2001), leading to release 
of viral particles (Figure 1). Subversion 
of host functions is a recurring theme in 
HIV-1 replication, and as such there have 
been numerous reciprocal exchanges 
of insight between researchers working 
on HIV-1 and in other areas of molecular 
and cellular biology.
One of the more exciting recent devel-
opments in AIDS research comes from 
the realization that HIV-1 replicates in 
an intrinsically hostile environment. Evo-
lution has endowed cells with factors 
that can directly inhibit retrovirus repli-
cation (Figure 1), presumably because 
retroviruses imparted recurrent selec- 133, May 16, 2008 ©2008 Elsevier Inc. 561
Figure 1. Key Steps in the HIV-1 Life Cycle
Viral proteins involved in each step are shown in blue, whereas cellular cofactors of host cells are shown 
in green. Host cell inhibitors of retrovirus replication are shown in red, and approved antiretroviral drugs 
targeting each step in the replication cycle are shown in pink. (Inset) Electron micrograph showing bud-
ding and immature HIV-1 particles (A), and a photomicrograph of a mature HIV-1 particle (B). (A, from 
Barré-Sinoussi et al., 1983; B, courtesy of J.A. Briggs and S.D. Fuller.)tive pressures during primate evolution. 
Moreover, a role for some HIV-1 auxiliary 
gene products in counteracting host 
inhibitors has been uncovered. A case in 
point, APOBEC3 cytidine deaminase of 
the host cell infiltrates retroviral particles 
during assembly and induces massive, 
lethal hypermutation and destabilization 
of the viral genome during subsequent 
reverse transcription (Sheehy et al., 
2002). Remarkably, the HIV-1 accessory 
protein Vif recruits APOBEC3 proteins to 562 Cell 133, May 16, 2008 ©2008 Elsevier Ia destructive ubiquitin ligase complex, 
thereby denuding the cell of this criti-
cal antiretroviral defense. Additionally, 
an inducible inhibitor of HIV-1 particle 
release, termed tetherin, whose activ-
ity is neutralized by the HIV-1 accessory 
protein Vpu, has recently been discov-
ered (Neil et al., 2008). Divergence in 
intrinsic antiretroviral molecules limits 
cross-species transmission of HIV-1 and 
other retroviruses; this characteristic has 
hampered the development of animal nc.models of AIDS. Indeed, the inability of 
HIV-1 to infect most nonhuman primate 
cells is determined partly by species-
specific variation in TRIM5α proteins 
that recognize and inactivate incoming 
retroviral capsids (Stremlau et al., 2004).
Our understanding of several aspects 
of HIV-1 replication has become highly 
evolved, and in some cases, structural 
and biochemical studies of HIV-1 pro-
teins have provided atomic resolution 
detail. For example, high-resolution 
imaging and structural studies of HIV-1 
Gag have revealed how viral particles 
assemble, and how the conical core in 
mature virions is formed (Figure 1, inset 
B). Structural and biochemical studies of 
the viral proteins reverse transcriptase, 
protease, integrase, and envelope have 
facilitated the development of antiret-
roviral drugs and provided mechanistic 
explanations for how certain viral muta-
tions confer drug resistance. Nonethe-
less, despite the highly detailed under-
standing of some aspects of HIV-1 
biology that have accrued, much remains 
to be learned. For example, our under-
standing of the events that occur during 
and between viral entry into the host cell 
and integration of the viral DNA into the 
host cell genome remains somewhat 
rudimentary. In addition, the precise role 
of HIV-1 Vpr and Nef continues to be elu-
sive, and structures of viral and relevant 
host proteins remain to be solved. These 
are major gaps that need to be filled, if 
a complete understanding of HIV-1 repli-
cation is to be achieved.
Pathogenesis
Much is known about HIV-1 pathogene-
sis in vivo. There is an acute burst of virus 
replication 2–3 weeks after transmission, 
when the infected person typically suf-
fers a flu-like illness. As this acute syn-
drome resolves spontaneously, concur-
rent with the onset of specific immune 
responses, the level of viremia is partially 
down-modulated, reaching a steady 
state or setpoint within a few months. 
Variable setpoints are observed among 
infected individuals, which determine the 
long-term prognosis of the infected per-
son (Mellors et al., 1996).
The HIV-1 setpoint is maintained by a 
dynamic equilibrium between virus pro-
duction and virus clearance (Wei et al., 
1995; Ho et al., 1995). Half of the virus 
particles in blood are cleared within ~30 
min, whereas half of the productively 
infected T cells die in ~0.7 days. To main-
tain the steady state, these parameters 
must be equally matched by newly pro-
duced virions and newly infected T cells. 
Such findings reveal extraordinary levels 
of HIV-1 replication in vivo that are con-
tinuous not only for days to months but 
for years to decades. Therefore, it is not 
surprising that such a remarkable level 
of virus replication has serious conse-
quences for the infected person. One 
adverse outcome is the loss of CD4+ T 
cells over time because virus replication 
is tightly coupled to a lymphocyte turn-
over rate that is heightened several-fold 
(Mohri et al., 2001). Both CD4+ and CD8+ 
T cell populations are activated, and the 
magnitude of this activation is propor-
tional to the viral load in plasma. It should 
also be noted that most of the T cells are 
turning over as the result of a generalized 
lymphocyte activation (that is, apoptosis 
that follows cellular proliferation) and not 
as the sequela of direct HIV-1 infection.
Another outcome of HIV-1 dynamics 
is the plasticity of viral sequences. High 
replication rates, in conjunction with the 
high error rate of reverse transcription, 
result in the creation of a massive num-
ber of new viral variants each day. Con-
sequently, swarms of diverse yet related 
viruses, known as quasispecies, appear 
within each infected person, and dis-
tinct HIV-1 subtypes or clades emerge 
within the global pandemic. This unprec-
edented degree of viral heterogeneity 
poses significant problems for immune 
recognition, antiretroviral therapy, and 
vaccine development.
Treatment
Our accrued understanding of HIV-1 rep-
lication has led to the development of 25 
approved antiretroviral drugs (Figure 1) 
and 5 fixed-dose combinations. Shortly 
after the discovery of the virus, a number 
of nucleoside analogs, previously devel-
oped for cancer or antibacterial chemo-
therapy, were screened for inhibitory 
activity against HIV-1 in vitro. Zidovudine 
became, in 1987, the first to be approved 
as an AIDS drug (Figure 1). Didanosine 
and several more followed, including a 
nucleotide analog, tenofovir. Essentially, 
the phosphorylated forms of these drugs 
serve to terminate DNA elongation during reverse transcription. Beginning in the late 
1980s, a class of non-nucleoside inhibi-
tors of reverse transcriptase emerged 
(Figure 1). Although structurally differ-
ent, each of these compounds binds to a 
common site on the reverse transcriptase 
to block its activity. By the early 1990s, 
and guided by a crystal structure, potent 
inhibitors of the HIV-1 protease began to 
appear. Such small molecules insert into 
the catalytic site and block polypeptide 
processing, thereby preventing virion 
maturation (Figure 1). Nevertheless, prior 
to 1995, all of the available protease and 
reverse transcriptase inhibitors were used 
individually or as dual-therapy, with only 
limited benefit to patients.
Antiretroviral therapy took on new life 
after the unraveling of HIV-1 dynam-
ics (Wei et al., 1995; Ho et al., 1995). 
This knowledge led to calculations that 
showed the rate of formation and accu-
mulation of mutations was so great that 
monotherapy and dual-therapy were 
doomed to fail because of the rapid 
emergence of drug resistance. On the 
other hand, the math also predicted 
that it was highly improbable (<10−8 per 
day) for HIV-1 to mutate in ≥3 positions, 
simultaneously, in a single genome. This 
realization led clinical investigators to 
pursue the use of three or more drugs 
in combination, starting in early 1995. By 
the time of the International AIDS Con-
ference in Vancouver in the summer of 
1996, it was clear that such combination 
antiretroviral therapy resulted in durable 
control of HIV-1 replication (Perelson et 
al., 1997). Viremia was reduced to below 
the level of detection for more than a 
year, and significant immunological and 
clinical recovery was observed.
Thus, 1996 marked a turning point 
in the AIDS pandemic. AIDS-associ-
ated mortality has since dropped by 
80%–90% in the US and Europe and, 
conservatively, more than 3 million per-
son-years of life have been saved. HIV-1 
infection is no longer an automatic death 
sentence; it is now a manageable dis-
ease. The therapeutic arsenal continues 
to improve with the advent of new reverse 
transcriptase and protease inhibitors, as 
well as two new classes of drugs target-
ing viral entry and integration (Figure 
1). This remarkable success story has 
become the model for drug development 
against other viral pathogens.CellSeveral daunting challenges in anti-
retroviral therapy remain, however. 
Although current combination therapy 
allows viral replication to be controlled, 
HIV-1 is not eradicated. It persists 
latently in resting memory CD4+ lym-
phocytes, and a cure is not possible 
until this reservoir is purged. In addi-
tion, there is a larger global problem of 
social injustice that must be addressed. 
About 90% of the infected population 
reside in developing countries where 
antiretroviral drugs are generally not 
available. Nascent efforts are now 
underway, led by the United Nations 
and the US government, to deliver 
treatment to poor regions of the world. 
But much more is needed and, sadly, 
apathy is a major obstacle to many 
more lives being saved.
Prevention
The HIV-1 epidemic continues to spread 
at the alarming rate of 2.5 million new 
cases per year despite educational 
efforts worldwide to modify behaviors 
at risk for infection. The use of topical 
microbicides to block viral transmission 
has been met with repeated disappoint-
ments. Most distressing, however, has 
been the inability of the scientific com-
munity to come up with a preventive 
vaccine. Approaches using whole inac-
tivated virus or envelope subunit pro-
tein have failed. Live attenuated forms 
of the simian immunodeficiency virus 
(SIV) have protected monkeys from a 
genetically matched SIV challenge (Dan-
iel et al., 1992), but such an approach in 
humans is generally deemed infeasible 
for safety reasons. Recently, a recombi-
nant adenoviral vector vaccine, designed 
to elicit cell-mediated immunity to the 
viral Gag, Pol, and Nef proteins, has also 
failed to demonstrate any hint of pro-
tection. HIV-1 vaccine development has 
now stalled and is desperately seeking 
new directions.
In retrospect, it is apparent that the 
field rushed forward with vaccine devel-
opment, bypassing a number of warn-
ing signs. It is well known that HIV-1 is 
rarely controlled by immune responses 
during the natural course of infection, 
an observation that does not bode 
well for a protective vaccine. Likewise, 
patients with superinfection have been 
well documented, showing that immu- 133, May 16, 2008 ©2008 Elsevier Inc. 563
Figure 2. Relationship of Primate Immunodeficiency Retroviruses
Shown are the phylogenetic relationships of primate immunodeficiency retroviruses (black lines), includ-
ing HIV-1 and HIV-2 in humans (red lines). The precursor of HIV-1 is a virus found in chimpanzees, SIVcpz, 
which is in turn the product of a recombination between SIVrcm (in red-capped mangabeys) and SIVgsn 
(in greater spot-nosed monkeys). (Phylogenetic relationships are based on a figure by M. Worobey; pho-
tos of nonhuman primates are courtesy of B. Hahn.)nity generated against one viral strain 
is often insufficient to block the trans-
mission of another. Lastly, it has long 
been appreciated that HIV-1 is relatively 
resistant to antibody neutralization, the 
basis of nearly all successful viral vac-
cines to date. Notwithstanding the tre-
mendous gains in understanding the 
structure of the viral envelope glycopro-
tein (Kwong et al., 1998), the scientific 
community has struggled to come up 
with any antigen design that will con-
sistently raise antibodies capable of 
penetrating the protective shield on the 
envelope glycoprotein created by vari-
able loops, extensive glycosylation, and 
entropic forces. A protective HIV-1 vac-
cine will likely remain elusive until this 
fundamental problem is solved.564 Cell 133, May 16, 2008 ©2008 Elsevier In the meantime, it should be kept in 
mind that HIV-1/AIDS is completely pre-
ventable. For example, the regular use 
of a condom during sexual intercourse 
would go a long way to stem the spread 
of this epidemic. Redoubling of a world-
wide effort to disseminate risk-reduction 
messages is absolutely essential.
Origin
It would serve us well to understand 
the origin of this devastating epidemic. 
HIV-1 belongs to a large family of pri-
mate retroviruses naturally found only 
in African nonhuman primates (Fig-
ure 2). The pandemic strains of HIV-1 
(group M) are, in all likelihood, derived 
from a single transmission event from 
a chimpanzee carrying SIVcpz to one Inc.human, probably in the vicinity of 
southern Cameroon (Keele et al., 2006). 
Molecular dating studies suggest that 
such a zoonosis took place some 60 to 
80 years ago (Korber et al., 2000). One 
could only speculate what led to the 
initial chimp-human transmission, and 
how its spread then became explosive 
decades later in Africa and beyond. Yet 
this example of zoonotic transmission 
is not alone among primate immunode-
ficiency viruses. Strains of HIV-1 rep-
resenting independent cross-species 
transmission events (groups N and O) 
are found in Africans living in proxim-
ity to chimpanzees harboring highly 
related SIVcpz (Figure 2). Moreover, 
HIV-2 in West Africans clearly traces 
its origins to multiple cross-species 
transmissions of SIVsmm from sooty 
mangabeys. Likewise, accidental trans-
missions of SIVsmm from sooty mang-
abeys to Asian macaques (SIVmac) in 
captivity resulted in infection and dis-
ease in the new host (Figure 2). One 
common theme has become evident: 
SIV in its natural host is typically non-
pathogenic (for example, SIVsmm in 
sooty mangabeys, SIVagm in African 
green monkeys, and SIVcpz in chim-
panzees), whereas transmission to a 
new host results in the virus becoming 
pathogenic (HIV-1 and HIV-2 in humans, 
SIVmac in macaques). Interestingly, the 
nonpathogenicity in the natural host is 
associated with a high efficiency of virus 
replication that is decoupled, for some 
unknown reason, from the generalized 
lymphocyte activation that character-
izes pathogenic infections in humans 
or macaques. Herein lies a clue to the 
secret of AIDS pathogenesis, perhaps.
Conclusion
The AIDS pandemic has presented 
unprecedented scientific, medical, and 
moral challenges to humanity. The 25 
years since the discovery of HIV-1 have 
been characterized by remarkable sci-
entific discoveries, as well as dramatic 
successes and failures in translating sci-
ence into effective interventions. Overall, 
significant advances have been made 
toward effectively tackling this modern-
day scourge. However, it is sobering 
to note that while the AIDS death toll is 
already staggering, the worst of this epi-
demic may lie ahead.
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